Kyverna Therapeutics Names Greg Martini CFO
(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18.
The late-stage clinical biopharmaceutical company focused on autoimmune diseases said Martini will succeed Marc Grasso.
Martini has been with Ironwood Pharmaceuticals. Kyverna will grant Martini an option to purchase 325,000 shares of its common stock Option.
The Company said it is in the process of advancing miv-cel or KYV-101 toward a potential first approval in stiff person syndrome and prepares for its transition to a commercial-stage organization.
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.